MoonLake Immunotherapeutics (MLTX) – What Are Researchers Saying About This Stock?

by · The Markets Daily

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $28.50.

Several research firms have issued reports on MLTX. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of MoonLake Immunotherapeutics in a research report on Monday, October 5th. Wall Street Zen downgraded MoonLake Immunotherapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, September 27th. Weiss Ratings raised MoonLake Immunotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of MoonLake Immunotherapeutics in a report on Wednesday, September 16th.

Check Out Our Latest Report on MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Trading Down 6.3%

Shares of MLTX opened at $11.78 on Friday. MoonLake Immunotherapeutics has a fifty-two week low of $9.46 and a fifty-two week high of $23.29. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -3.07 and a beta of 1.08. The firm has a 50 day moving average price of $12.52 and a 200-day moving average price of $16.47. The company has a debt-to-equity ratio of 0.23, a quick ratio of 12.56 and a current ratio of 12.56.

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.07. As a group, equities research analysts forecast that MoonLake Immunotherapeutics will post -3.34 earnings per share for the current year.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of large investors have recently bought and sold shares of the stock. Weiss Asset Management LP increased its stake in shares of MoonLake Immunotherapeutics by 413.1% in the first quarter. Weiss Asset Management LP now owns 1,708,328 shares of the company’s stock worth $31,843,000 after buying an additional 1,375,367 shares during the period. Candriam S.C.A. raised its holdings in MoonLake Immunotherapeutics by 509.0% during the 1st quarter. Candriam S.C.A. now owns 818,126 shares of the company’s stock valued at $15,250,000 after buying an additional 683,797 shares during the last quarter. Janus Henderson Group PLC raised its holdings in MoonLake Immunotherapeutics by 64.7% during the 1st quarter. Janus Henderson Group PLC now owns 3,451,628 shares of the company’s stock valued at $64,304,000 after buying an additional 1,355,640 shares during the last quarter. Exome Asset Management LLC purchased a new stake in MoonLake Immunotherapeutics during the 1st quarter valued at $4,015,000. Finally, Engineers Gate Manager LP purchased a new stake in MoonLake Immunotherapeutics during the 2nd quarter valued at $2,173,000. 93.85% of the stock is owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Company Profile

(Get Free Report)

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases. The company is advancing medicines designed to address conditions in which the immune system contributes to chronic inflammation and tissue damage.

Its lead product candidate is sonelokimab, an investigational Nanobody-based therapy designed to selectively inhibit interleukin-17A and interleukin-17F, two cytokines involved in inflammatory disease.

Recommended Stories